← boardnext 2026-08next 2026-09next 2026-09next 2026-12next 2026-12next 2027-01next 2027-03next 2027-07next 2027-08next 2028-01next 2028-05next 2028-06next 2028-06next 2028-09next 2028-11next 2028-12next 2029-01next 2029-03next 2029-06next 2029-10next 2030-01next 2030-02next 2030-10
GILD
Gilead Sciencesdistress 2/10 · well-funded / low risk$128.47-1%today-18% from 52w high
Oncology 1
Lead: Triple Negative Breast Cancer · target TIGIT · est. market ~$35B (approx, global)
Revenue
$6960M
Liquidity
$8626M
Runway
—
Shares 1y
+0%
Price & events
-0.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-5.7%
1W
+2.7%
1M
-3.2%
3M
-4.3%
6M
+16.1%
1Y
+91.2%
2Y
+123.4%
5Y
+162.1%
All
Overview
- Market Cap
- $159.50B
- Enterprise Value
- $172.73B
- Volume
- 425.60K
- 52 Week Range
- $108 – $156
- Total Shares
- 1.24B
- Float Shares
- 1.24B
- Short %
- 2.05%
- % Held by Insiders
- 0.12%
- % Held by Institutions
- 92.21%
- RVOL
- 0.06x
- Beta
- 0.34
Pipeline stages · 23 programs
Domvanalimab, Quemliclustat, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TAF
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-9911, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tilpisertib Fosmecarbil
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Lenacapavir, BIC/LEN FDC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KTE-X19, Cyclophosphamide, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Lepetegravir, Lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 23 programs · 13 more ▾
GS-5319
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-2121, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-0201, Sacituzumab Govitecan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Seladelpar
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Denikitug, Nivolumab, Ramucirumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-2426
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
zamzetoclax, Docetaxel, sacituzumab govitecan-hziy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KITE-753, Axicabtagene Ciloleucel, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GS-4321
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Cyclophosphamide, Fludarabine, KITE-363
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 44 trials · 44 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 final ~2027-08-31 | Phase 2 | Domvanalimab, Zimberelimab, Paclitaxel | Head and Neck Squamous Cell Carcinoma | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin | Non-small Cell Lung Cancer | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | TAF | Chronic Hepatitis B | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | Sacituzumab Govitecan-hziy | Solid Tumor | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product | Metastatic Breast Cancer | — | active not recruiting |
Show all 44 trials · 39 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | anitocabtagene-autoleucel | Multiple Myeloma | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | Sacituzumab Govitecan-hziy | Advanced or Metastatic Solid Tumor, Liver Failure | — | recruiting |
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | GS-9911, Zimberelimab | Solid Tumors | — | active not recruiting |
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | Tilpisertib Fosmecarbil | Ulcerative Colitis | — | recruiting |
| 2027-02 Estimated 50% readout ~2027-04-17 | Phase 3 | Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel | Triple Negative Breast Cancer, PD-L1 Positive | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR) | HIV-1-infection | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine | Triple Negative Breast Cancer | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 2 | KTE-X19, Cyclophosphamide, Fludarabine | Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | — | active not recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet | HIV-1-infection | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | Domvanalimab, Quemliclustat, Zimberelimab | Advanced Non-Small Cell Lung Cancer | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 2/3 | Lepetegravir, Lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide | HIV-1-Infection | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/ | Pre-Exposure Prophylaxis of HIV Infection | — | active not recruiting |
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 3 | Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel | Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer | — | active not recruiting |
| 2028-05 Estimated 50% readout ~2028-05-31 | Phase 1 | GS-5319 | Advanced Solid Tumor | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-07-01 | Phase 1 | GS-2121, Zimberelimab | Advanced Solid Tumors | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Zimberelimab, Domvanalimab, Pembrolizumab | Non-small Cell Lung Cancer | — | active not recruiting |
| 2028-06 Estimated 50% readout ~2028-07-16 | Phase 1/2 | Sacituzumab Govitecan-hziy (SG) | Triple Negative Breast Cancer | — | recruiting |
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel | Triple Negative Breast Cancer, PD-L1 Negative | — | active not recruiting |
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine | Multiple Myeloma | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-10-01 | Phase 1 | GS-0201, Sacituzumab Govitecan | Advanced Solid Tumors | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | Lenacapavir Injection, Lenacapavir Tablet | HIV Pre-exposure Prophylaxis | — | active not recruiting |
| 2028-11 Estimated 50% readout ~2029-01-15 | Phase 3 | Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule | Primary Biliary Cirrhosis | — | active not recruiting |
| 2028-12 Estimated 50% readout ~2028-12-31 | Phase 1 | Denikitug, Zimberelimab | Advanced Solid Tumor | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 2 | Denikitug, Nivolumab, Bevacizumab | Advanced Microsatellite Stable Colorectal Cancer | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-01-31 | Phase 1 | GS-2426 | Advanced Solid Tumors | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-03-31 | Phase 1 | zamzetoclax, Docetaxel, sacituzumab govitecan-hziy | Solid Malignancies | — | active not recruiting |
| 2029-06 Estimated 50% readout ~2029-07-01 | Phase 1 | KITE-363, Fludarabine, Cyclophosphamide | Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis | — | recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel | Endometrial Cancer | — | active not recruiting |
| 2029-09 Estimated 50% readout ~2029-10-16 | Phase 2 | Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG) | Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer | — | active not recruiting |
| 2029-10 Estimated 50% readout ~2029-12-15 | Phase 3 | Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | — | recruiting |
| 2030-01 Estimated 50% readout ~2030-02-15 | Phase 1/2 | GS-4321 | Chronic Hepatitis Delta | — | recruiting |
| 2030-01 Estimated 50% readout ~2030-02-15 | Phase 2 | Denikitug, Nivolumab, Ramucirumab | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | — | recruiting |
| 2030-02 Estimated 50% readout ~2030-03-18 | Phase 1/2 | Cyclophosphamide, Fludarabine, KITE-363 | Relapsed and/or Refractory B-cell Lymphoma | — | recruiting |
| 2030-04 Estimated 50% readout ~2030-05-16 | Phase 2 | Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin | Metastatic Urothelial Cancer | — | recruiting |
| 2030-07 Estimated 50% readout ~2030-09-14 | Phase 2/3 | Lenacapavir, BIC/LEN FDC | HIV-1-infection | — | active not recruiting |
| 2030-08 Estimated 50% readout ~2030-10-15 | Phase 3 | Seladelpar | Primary Biliary Cholangitis | — | recruiting |
| 2030-10 Estimated 50% readout ~2030-12-15 | Phase 3 | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine | Relapsed/Refractory Follicular Lymphoma | — | active not recruiting |
| 2031-03 Estimated 50% readout ~2031-05-15 | Phase 3 | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine | High-risk Large B-cell Lymphoma (LBCL) | — | active not recruiting |
| 2031-05 Estimated 50% readout ~2031-07-15 | Phase 3 | KITE-753, Axicabtagene Ciloleucel, Fludarabine | Relapsed or Refractory Large B-cell Lymphoma | — | recruiting |
Catalyst news & presentations · 4
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-28partnershipanito-cel · Gilead acquires Arcellx for $115/share plus CVR up to $5/share based on $6B sales milestoneSEC 8-K
- 2026-02-22partnershipGilead Sciences to acquire Arcellx, Inc. for $115 per share plus contingent value rights of $5 per share.SEC 8-K
- 2025-10-06partnershipBiktarvy · Resolved patent litigations with Lupin, Cipla, Laurus Labs; no generic entry before April 1, 2036.SEC 8-K
Approved drugs (14)
- HEPCLUDEXBULEVIRTIDE-GMOD2026 · Prescription
- YEZTUGOLENACAPAVIR SODIUM2025 · Prescription
- YEZTUGOLENACAPAVIR2025 · Prescription
- LIVDELZISELADELPAR LYSINE2024 · Prescription
- SUNLENCALENACAPAVIR SODIUM2022 · Prescription
- SUNLENCALENACAPAVIR SODIUM2022 · Prescription
- EPCLUSASOFOSBUVIR2021 · Prescription
- VEKLURYREMDESIVIR2020 · Discontinued
- HARVONILEDIPASVIR2019 · Prescription
- SOVALDISOFOSBUVIR2019 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $158 (+23% upside) · 27 analysts
- 2026-07-21Leerink PartnersOutperform → Market Perform
- 2026-07-08Morgan StanleyOverweight
- 2026-07-07Truist SecuritiesBuy
- 2026-07-07RBC CapitalSector Perform
- 2026-07-06Cantor FitzgeraldOverweight
- 2026-07-06HSBCHold → Buy
Competitors — TIGIT
- RCUSArcus Biosciences, Inc.$3.8B · D5
Recent news
- 2026-07-23ETFs Investing in Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Stocks - TradingView
- 2026-07-21Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
- 2026-07-21ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
- 2026-07-21Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
- 2026-07-21Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
- 2026-07-21Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Gilead Sciences
- 2026-07-21Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
- 2026-07-21Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.